Company Overview and News

0
Kobe Steel and plant officials referred to prosecutors over data falsification scandal

2018-07-17 japantimes.co.jp
Police referred Kobe Steel Ltd. and four of its plant officials to prosecutors Tuesday over a scandal that involved fabricating data related to the quality of its products, investigative sources said.
5406 KBSTF KBSTY TM 5711 MIMTF 7203 TYT TOYOF

0
Nissan Falsifies Exhaust Emission Data in New Issue for Saikawa - Bloomberg

2018-07-10 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
5406 VLKAF KBSTF MMTOY KBSTY 7269 DDAIF 7211 MMTOF

0
Nissan Says It Found ‘Misconduct' in Exhaust, Fuel Economy Tests - Bloomberg

2018-07-09 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
5406 VLKAF KBSTF MMTOY KBSTY 7269 7211 MMTOF

0
Nissan says it found ‘misconduct’ in exhaust, fuel economy tests

2018-07-09 thestar
This copy is for your personal non-commercial use only. To order presentation-ready copies of Toronto Star content for distribution to colleagues, clients or customers, or inquire about permissions/licensing, please go to: www.TorontoStarReprints.com
5406 VLKAF KBSTF MMTOY KBSTY 7269 7211 MMTOF

0
Nissan admits to more testing misconduct for cars sold in Japan

2018-07-09 theedgemarkets
YOKOHAMA (July 9): Nissan Motor said on Monday it had improperly measured exhaust emissions and fuel economy for 19 vehicle models sold in Japan, the second case in less than a year where misconduct has been discovered in its inspection processes.
5406 KBSTF KBSTY

0
Nissan admits to more testing misconduct for cars sold in Japan

2018-07-09 reuters
YOKOHAMA (Reuters) - Nissan Motor (7201.T) said on Monday it had improperly measured exhaust emissions and fuel economy for 19 vehicle models sold in Japan, the second case in less than a year where misconduct has been discovered in its inspection processes.
5406 KBSTF KBSTY

0
Nissan says exhaust tests were altered in latest scandal

2018-07-09 japantimes.co.jp
Nissan Motor Co. said Monday that it altered the results of tests on exhaust emissions and fuel economy of new vehicles for domestic sale, in the latest case of misconduct to surface at the Japanese automaker.
5406 KBSTF KBSTY

0
Nissan shares tumble ahead of emissions briefing

2018-07-09 reuters
TOKYO (Reuters) - Shares in Nissan Motor Co (7201.T) on Monday slumped about 5 percent to their lowest level in more than a year after the automaker said it would hold a briefing regarding its procedures to measure vehicle exhaust gas at its domestic plants.
5406 KBSTF KBSTY

0
Nissan shares tumble ahead of emissions briefing - Channel NewsAsia

2018-07-09 channelnewsasia
TOKYO: Shares in Nissan Motor Co on Monday slumped about 5 percent to their lowest level in more than a year after the automaker said it would hold a briefing regarding its procedures to measure vehicle exhaust gas at its domestic plants.
5406 KBSTF KBSTY

1
Hitachi affiliate discovers data fraud involving 60,000 batteries

2018-06-29 japantimes.co.jp
An affiliate of Japanese electronics giant Hitachi Ltd. admitted Friday it had falsified data for 60,000 industrial batteries, the latest in a series of similar scandals that has battered the country’s reputation for quality.
4217 5406 KBSTF KBSTY 6501 5711 MIMTF HTHIY

0
Mitsubishi Materials president to step down over data tampering scandal

2018-06-11 japantimes.co.jp
Mitsubishi Materials Corp. said Monday its president, Akira Takeuchi, will step down to take responsibility for a slew of product quality falsifications at the nonferrous metal group.
5406 KBSTF KBSTY 5711 MIMTF

0
Mitsubishi Materials unveils boardroom shake-up as data tampering scandal deepens

2018-06-11 channelnewsasia
Japan's Mitsubishi Materials Corp on Monday announced a top management reshuffle after the maker of metals and other products for the first time explicitly accepted responsibility over a data tampering scandal dating back to last year.
5406 KBSTF KBSTY 3402 5711 MIMTF TRYIY TRYIF

0
Mitsubishi Materials unveils boardroom shake-up as data tampering scandal deepens

2018-06-11 reuters
TOKYO (Reuters) - Japan’s Mitsubishi Materials Corp (5711.T) on Monday announced a top management reshuffle after the maker of metals and other products for the first time explicitly accepted responsibility over a data tampering scandal dating back to last year.
5406 KBSTF KBSTY 3402 5711 MIMTF TRYIY TRYIF

0
Mitsubishi Materials admits to labeling substandard concrete-making material with JIS certification

2018-06-08 japantimes.co.jp
Mitsubishi Materials Corp. said Friday that material used to make concrete was mistakenly shipped out with a Japan Industrial Standard certification label even though it was actually substandard.
5406 KBSTF KBSTY 5711 MIMTF

0
Chemical maker Ube Industries reports quality-control misconduct dating back to ’70s

2018-06-07 japantimes.co.jp
Ube Industries Ltd. said Thursday that an internal probe found the maker of chemical products might been conducting improper quality checks since the 1970s.
5406 KBSTF 4208 KBSTY UBEOY UBEOF

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

CUSIP: J34555144